COMP <GO>
ATHE vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Alterity Therapeutics Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ATHE 0
— JNJ 2
■ METRIC PARITY
LAST: $2.23 (+2.93%) • MKT CAP: $40.7M
roic
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATHE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATHE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | 25.50% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 34.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 28.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 6.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 8/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.6 | 62.1 | -36.54 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.7M | $662.49B | -$662.45B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATHE REV | JNJ REV | ATHE GROSS % | JNJ GROSS % | ATHE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $94.19B | — | 67.9% | — | $19.70B |
| FY 2024 | — | $88.82B | — | 69.1% | — | $19.84B |
| FY 2023 | — | $85.16B | — | — | — | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATHE // BETA —
JNJ // BETA 1.08